A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 on ClinicalTrials.gov · last registry update 2026-08-21
An unusually large phase 2: 240 participants, more than double the 114 typical for the stage. Due to report December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 240
- Started
- 2025-03-28
- Primary completion
- 2026-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.